Table 3.

Model 2 adjusted linear regression results between a blood biomarker and an imaging biomarker

	Serum NfL			Plasma NTA			Plasma t-tau			Plasma GFAP
Predictors	Estimate	R2	p	Estimate	R2	p	Estimate	R2	p	Estimate	R2	p
WMH, slope (95% CI)	0.0088 (0.0019 to 0.016)	0.33	0.021	0.007 (-0.011 to 0.025)	0.027	0.54	-0.004 (-0.012 to 0.0037)	0.11	0.37	0.0037 (-0.0054 to 0.013)	0.015	0.51
MTA, slope (95% CI)	0.13 (0.019 to 0.24)	0.32	0.049	0.44 (0.13 to 0.76)	0.15	0.022	-0.12 (-0.010 to 0.25)	0.14	0.13	0.22 (0.075 to 0.36)	0.15	0.022
PiB, slope (95% CI)	0.14 (-0.026 to 0.30)	0.20	0.16	0.12 (-0.33 to 0.56)	-0.054	0.62	0.05 (-0.15 to 0.25)	0.045	0.61	0.27 (0.073 to 0.47)	0.13	0.022

Serum NfL = neurofilament light, Plasma NTA = N-terminal tau marker, Plasma t-tau = Quanterix total tau marker, Plasma GFAP = glial fibrillary acidic protein, WMH = volumes of white matter hyperintensities, MTA = medial temporal lobe atrophy score, PiB = [¹¹C]PiB composite score. Blood biomarker values are log transformed. Results adjusted for Age, Sex and BMI. WMH and MTA also adjusted for MRI scanner. Significant values are bolded. P-values are FDR-corrected including all p-values from tables 1, 2, 3, and 4. Blood biomarker values were log transformed